Yubo International Biotech Limited (YBGJ) is a China-based biotech and consumer healthcare company that researches, develops, and sells stem cell-related health products and services through its variable interest entity, Yubo Beijing. Revenue is generated through the sale of consumer healthcare products and stem cell services, including cell testing and health management consulting, all marketed under the brand VIVCELL. Yubo Beijing's product portfolio spans respiratory healthcare, skincare, eye care, hair care, healthy beverages, and male and female personal care products, each formulated with growth factor polypeptide cell technology including FGF, EGF, and VEGF. The company is a U.S.-listed holding company incorporated in New York, operating entirely in China through contractual VIE arrangements. Yubo Beijing is also working toward establishing what it describes as the first public endometrial stem cell repository, with manufacturing facilities under construction in Chengdu as of the 10-K filed March 31, 2026. Commercial-scale manufacturing currently relies on third-party contract manufacturing organizations.

Revenue model

Transactional sales of consumer healthcare products under the VIVCELL brand, supplemented by stem cell services including cell testing and health management consulting. All operations are conducted through Yubo Beijing via VIE contractual arrangements.

Products and services

VIVCELL-branded consumer healthcare products: respiratory system products, skincare products, eye care series (eye moist essence applied via warm import instrument), hair care series (hair follicle essence applied via nano-crystal injector), healthy beverages, bacteriostatic spray and intimate wash for men and women, nourishing vagina essence. Stem cell services: cell testing, health management consulting. Endometrial stem cell repository under development.

Customers and end markets

Consumers in China with specific health conditions: individuals suffering from dry eyes or post-eye-surgery recovery (eye care); high-income individuals with hair thinning, scalp damage, or severe hair loss (hair care); individuals seeking personal hygiene and infection prevention (private care series). Stem cell services target health management clients.

Value-chain role

Research and development of stem cell-derived formulations and consumer health products; product commercialization under VIVCELL brand; reliance on third-party CMOs for current manufacturing; stem cell bank and regional manufacturing hub (Chengdu) under construction as of 10-K filed March 31, 2026.

Geographic exposure

All operations located in China. U.S. holding company structure with Cayman Islands and Hong Kong intermediaries. Operates through VIE Yubo Beijing.

Source: SEC 10-K, filed 2026-03-31

Industry: Electromedical & Electrotherapeutic Apparatus